#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hyperoxaluria Ehlers-Danlos syndrome Haemophilia A without inhibitors Hyperadrenocorticism Vulval cancer recurrent Mixed-type liposarcoma Mucopolysaccharidosis III Pustular psoriasis Chronic hepatitis B Neuronal ceroid lipofuscinosis Astrocytoma malignant Aplastic anaemia Scleroderma associated digital ulcer Obliterative bronchiolitis Osteomyelitis More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory – Treatment Marginal zone lymphoma Small intestine leiomyosarcoma – Diagnostics Pulmonary sarcoidosis – Trials in Disease Myelodysplastic syndrome – Life with Disease Angiosarcoma recurrent – Treatment Ehlers-Danlos syndrome – Diagnostics Hypereosinophilic syndrome – Life with Disease Krabbe’s disease – Treatment Sjogren’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ide397 GSK3862995B Nystatin Burfiralimab Sulfonamides, Urea Derivatives Alnuctamab Tropicamide Morf-057 Pazopanib Aup1602-C Epinephrine Hydrochloride Fedratinib Alitretinoin Zinc Oxide Timothy Grass Pollen Extract Anb032 Gliquidone BI-1607 RNMB1 Ibuprofen Sodium Dihydrate More therapies…

    Learn about Your Condition

    Osteoporosis Proteinuria Acarodermatitis Sinusitis bacterial Neonatal respiratory failure Neoplasm Iron deficiency Mantle cell lymphoma stage II Neoplasm malignant Primary hypercholesterolaemia Thrombotic microangiopathy Perthes disease Sarcoma metastatic Spina bifida Glioblastoma multiforme More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Zoledronic Acid for Treating Osteosarcoma in Children, Adolescents, and Adults

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Zoledronic Acid Monohydrate
    France

  • Study on Durvalumab for Patients with Poor General Condition and Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • General physical health deterioration
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Durvalumab
    France

  • Study on Talazoparib for Maintenance Treatment in Patients with Advanced Malignant Pleural or Peritoneal Mesothelioma After Initial Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    • Peritoneal mesothelioma malignant
    Investigated Drugs:
    • Talazoparib
    France

  • Study of hyperthermic intraperitoneal chemotherapy with oxaliplatin, fluorouracil, and calcium levofolinate in patients with advanced gastric cancer after surgery

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Calcium Levofolinate
    • Fluorouracil
    • Oxaliplatin
    France

  • Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Petosemtamab
    • Cetuximab
    • Docetaxel
    Belgium Czechia France Germany Greece Hungary +6

  • Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    Belgium France

  • Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Everolimus
    • Placebo
    Belgium France

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France

  • Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Camizestrant
    • Fulvestrant
    Belgium France Hungary Italy Poland Portugal +1

  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Camizestrant
    Austria Belgium Bulgaria France Germany Hungary +6
Previous Page
1 … 11 12 13 14 15 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!